Tonix Pharmaceuticals appoints Joseph Hand as General Counsel and EVP of Operations

Tonix Pharmaceuticals Holding Corp.

Joseph Hand appointed General Counsel and EVP of Operations, effective May 14, 2025.
Hand brings over 20 years biopharma experience; served on Celgene's Executive Committee for nearly a decade.
Played key roles in Celgene's $74B acquisition by BMS and $13.4B divestiture of Otezla to Amgen.
Appointment comes as Tonix prepares for potential FDA approval of TNX-102 SL for fibromyalgia by August 15, 2025.
Hand previously served as Chief Administrative Officer at Phathom Pharmaceuticals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.